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Background: Cancer-associated bone disease is a serious complication in bone sarcomas and metastatic carcino-
mas of breast and prostate origin.Monoacylglycerol lipase (MAGL) is an enzyme of the endocannabinoid system,
and is responsible for the degradation of the most abundant endocannabinoid in bone, 2-arachidonoyl glycerol
(2AG).
Methods: The effects of the verified MAGL inhibitor on bone remodelling were assessed in healthy mice and in
mouse models of bone disease caused by prostate and breast cancers and osteosarcoma.
Findings: JZL184 reduced osteolytic bone metastasis in mouse models of breast and prostate cancers, and
inhibited skeletal tumour growth, metastasis and the formation of ectopic bone in models of osteosarcoma. Ad-
ditionally, JZL184 suppressed cachexia and prolonged survival in mice injected with metastatic osteosarcoma
and osteotropic cancer cells. Functional and histological analysis revealed that the osteoprotective action of
JZL184 in cancer models is predominately due to inhibition of tumour growth and metastasis. In the absence
of cancer, however, exposure to JZL184 exerts a paradoxical reduction of bone volume via an effect that is medi-
ated by both Cnr1 and Cnr2 cannabinoid receptors.
Interpretation:MAGL inhibitors such as JZL184, or its novel analogues, may be of value in the treatment of bone
disease caused by primary bone cancer and bonemetastasis, however, activation of the skeletal endocannabinoid
system may limit their usefulness as osteoprotective agents.
© 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Monoacylglycerol lipase (MAGL) is a major enzyme of the endoge-
nous cannabinoid (endocannabinoid) system that plays a role in
neurotransmission, lipolysis and neuroinflammation [1–3]. MAGL is re-
sponsible for the degradation of the endocannabinoid 2-arachidonoyl
glycerol (2AG) - the most abundant endocannabinoid, and acts as a
precursor to fatty acids [1,3]. Over recent years, a number of studies
have shown that various types of tumours including breast and prostate
carcinomas express MAGL [1,2,4], and its elevated level has been linked
to malignancy, metastasis and poor patient prognosis and clinical out-
comes [5–7]. In 2011, Nomura and colleagues uncovered the role of
cancer-specific MAGL in prostate cancer progression, and showed that
the verified MAGL inhibitor JZL184 reduced prostate cancer cell tumour
growth and earlymetastasis by amechanism that is dependent on levels
of the 2AG and free fatty acids (FFA) [1,4].
The skeleton is a common site to metastatic cancer cells of various
origin including prostate and breast, and the birthplace of bone sarcoma
cells [8–14]. Disruption of the activity of immune and bone cells in
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particular the bone resorbing osteoclasts by cancer cells is a major con-
tributory factor to the devolvement and progression of cancer associ-
ated bone disease [8–10,15,16]. Thus, treatments aimed at halting
metastasis, reducing skeletal tumour growth, and attenuating osteo-
clastic bone damage would prove to be beneficial in terms of clinical
outcomes in advanced cancer patients. Whilst the role of MAGL in can-
cer associated bone disease is unknown, the MAGL metabolite 2AG and
its cannabinoid receptors (Cnr) have been previously implicated in the
regulation of bone remodelling in health and disease [17–19].
The endocannabinoid 2AG is secreted in the skeleton by osteoblasts,
osteoclasts and immune cells at levels similar to those present in the
brain [19–25]. 2AG binds to cannabinoid receptors (Cnr) type 1 and 2
with varying degree of selectivity, and both Cnr1 and 2 have been
found to be expressed by bonemarrow, osteoblasts, osteoclasts and im-
mune cells [3,26,27]. Skeletal analysis of transgenic animals showed
that mice lacking Cnr1 or Cnr2 receptors develop osteoporosis with in-
creasing age due to increased bone turnover [22,28–32], whereas ge-
netic inactivation of both receptors in mice reduced age-related bone
loss due to a reduction in osteoclast number [33]. Together, these find-
ings consolidate the role of the endocannabinoid system in the regula-
tion of bone remodelling.
Encouraged by thefindings of Nomura et al. that implicated the2AG/
MAGL axis in the prostate cancer initiation and progression [4], and the
propensity of prostate cancer to metastasise to the skeleton [8–11,13],
we tested the effects of MAGL knockdown and pharmacological inhibi-
tion on skeletal tumour burden, bone metastasis and osteolytic bone
damage in preclinicalmodels of bonedisease associated cancers of pros-
tate, breast and skeletal origin. Here, we report thatMAGL inhibition re-
duced the initiation and progression of cancer related bone disease in
models of secondary prostate and breast cancer in bone and osteosar-
coma by a mechanism dependent – at least in part - on reduction of
skeletal tumour growth and inhibition of osteolytic metastasis. In the
absence of cancer, however, we show that exposure of host cells to
the verified MAGL inhibitor JZL184 enhanced osteoclast formation and
caused bone loss via a cannabinoid receptor dependent effect. Collec-
tively, the results of the present finding implies that MAGL inhibitors
such as JZL184, or its novel analogues, may be of value in the reduction
of skeletal tumour burden and osteolysis caused by primary bone
cancer and bone metastasis, however, activation of the skeletal
endocannabinoid system may limit their usefulness as osteoprotective
agents.
2. Materials and methods
2.1. Reagents and chemicals
The endocannabinoid 2AG and MAGL inhibitor JZL184 were pur-
chased from Tocris Biosciences (Bristol, UK). The parental human breast
MDA-MB-231, prostate PC3, osteosarcoma KHOS and Saos-2 were pur-
chased from ATCC (Manassas, VA). The mouse osteosarcoma cells MOSJ
were originally purchased from ATCC (Manassas, VA) and were a kind
gift fromProfessor DominiqueHeymann (INSERM,University of Nantes,
France). The osteotropic human breast cancer cell lineMDA-MB-231-BT
(MDA-231-BT) was generated by Dr. Nadia Rucci (University of
L'Aquila, Italy) and the osteotropic human prostate cancer cell line
PC3-BT was a kind gift by Dr. Ning Wang (University of Sheffield, UK).
Single cell clones of MDA-MB-231 were expanded and injected into
the left ventricle of 4-week-old female BALB/c-nu/nu mice. A clone
that generated bone-only lesions with significant osteolysis in 8-
weeks was used [34–37]. Tissue culture medium (D-Modified Eagle
Medium (MEM) and alpha-MEM) was obtained from Sigma-Aldrich
(Dorset, UK). All primary antibodies were purchased from Cell Signal-
ling Biotechnology (MA, USA) except rabbit anti-actin, which was ob-
tained from Sigma-Aldrich (Dorset, UK). Mouse macrophage colony
stimulating factor (M-CSF) was obtained from R&D Systems (Abingdon,
UK) and receptor activator of NFκB ligand (RANKL) was a gift from Pat-
rick Mollat (Galapagos SASU, France).
2.2. Animal experiments
All procedures involving mice and their care were approved by and
performed in compliance with the guidelines of Institutional Animal
Care and Use Committee of Universities of Edinburgh (Scotland, UK),
L'Aquila (L'Aquila, Italy) and Nantes (Nantes, France), and received in-
stitutional approval and conducted in conformitywith laws and policies
(UK Home Office and Italian and French authorities). C57BL/6 J and
BALB/c-nu/nu mice were obtained from Harlan (UK) and Charles River
(Milan, Italy), respectively. Six week-old female CD1 mice deficient in
Cnr1 and Cnr2 receptors were generated as described in33.
2.2.1. Intracardiac injection of human MDA-231-BT and PC3-BT tumour
cells
Eight week-old female BALB/c-nu/nu athymic mice were anesthe-
tized with intraperitoneal injections of pentobarbital (60 mg/kg). Can-
cer cells re-suspended in PBS and intra-cardiacly injected (2 × 106
cells) (8 mice per group). Animals were divided into two/three groups
and received intraperitoneal injection of either vehicle (water) or
JZL184 (8-16mg/kg). Animals were daily monitored for cachexia (eval-
uated by body weight waste), behaviour, and survival. At the end of the
experiments, mice were euthanized by CO2 inhalation. Development of
metastasis in bone was monitored by Bioluminescence imaging (PC3)
using a IVIS SpectrumCT In Vivo Imaging System (PerkinElmer, UK)
and X-ray analysis (PC3-BT and MDA-231-BT)(36 KPV for 10 s) using
a Cabinet X-ray system (Faxitron model n.43855A; Faxitron X-Ray
Corp., Buffalo Grove, IL, USA) and Radiographs were scanned using the
Bio-Rad scanning densitometer (Hercules, CA, USA), model GS800,
and quantification of the area of interest was done using the Bio-Rad
Research in context
Evidence before this study
Cancer-induced bone disease is a serious complication in bone sar-
comas and metastatic carcinomas of breast and prostate origin.
Cannabinoids and their receptors (Cnr) are implicated in cancer
and bone remodelling, while monoacylglycerol lipase (MAGL), an
enzyme responsible for the degradation of the most abundant
endocannabinoid in bone 2-arachidonoyl glycerol (2AG), has
been shown to regulate tumour growth and early metastasis.
Added value of this study
Using mouse models of advanced breast and prostate cancer and
osteosarcoma, we report that the verified MAGL inhibitor
JZL184 inhibited cancer-related bone damage, reduced skeletal
tumour growth, suppressed cachexia and prolonged survival. In
the absence of cancer, however, exposure to JZL184 exerts a par-
adoxical reduction of bone volume via an effect that ismediated by
cannabinoid receptors.
Implications of all the available evidence
In this study,we provide new insight in the role of theMAGL/2AG/
Cnr axis in normal and cancer-related bone remodelling, and con-
clude that targeting MAGL is of potential therapeutic efficacy in
primary bone cancer and bone metastasis. However, we caution
that activation of the skeletal endocannabinoid system in absence
of cancer may limit the usefulness of MAGL inhibitors as
osteoprotective agents.
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Quantity One image analysis software. At the end of the experiment
(55 days from tumour-cell injection), mice were euthanized and sub-
jected to micro-computed tomography (microCT) analysis and to ana-
tomical dissection for evaluation of bone and visceral metastases,
respectively. Skeletal tumour growth wasmeasured on 2DmicroCT im-
ages using Image J (1.34 s; NIH, Bethesda, MD, USA) and results were
expressed as a percentage of total metaphyseal area.
2.2.2. Para-tibial injection of human KHOS andmouseMOS-J osteosarcoma
cells
Sixteen female NMRI athymic nude mice 5-week-old mice received
para-tibial injection of humanMNNG/HOS osteosarcoma cancer cells (2
× 106 cells) and 16 female C57BL/6j 6-week old mice received para-
tibial injection of mouse MOSJ osteosarcoma cancer cells (2 × 106
cells) or a sham injection of PBS into their right leg. Animals were di-
vided into two groups (n = 8) and received intraperitoneal injection
of either vehicle (water) or JZL184 (16 mg/kg). Animals were eutha-
nized 35 days post injection and bones were analyzed by microCT
(Skyscan 1172 scanner). Lung metastasis and osteolysis were assessed
as described above.
2.3. Histomorphometry
Metastatic bones were fixed in buffered 4% formaldehyde and
decalcified for 3 weeks. Bone histomorphometry was performed on
the proximal tibial metaphysis from mice as previously described [38].
In short, bones were fixed, sectioned using a Leica microtome (Solms,
Germany) and tissue sections KHOS model were stained with tartrate-
resistant acid phosphatase (TRAcP) and haematoxylin and eosin
(H&E). Histomorphometry was performed on trabecular bone distal
from the growth plate (0.1 and 1mm distal to the growth plate). Bone
histomorphometrical analysis was performed as previously described.
Metastatic bones from the PC3-BT and MDA-231-BT were stained
with H&E and osteoclasts and osteoblasts were identified by morphol-
ogy and contact with the bone. Histomorphometric measurements
were carried out on 4 μm thick sections, with an interactive image anal-
ysis system (Osteomeasure, Osteometrics Inc. Atlanta). Nomenclature,
symbols and units of morphometric bone variables were used as previ-
ously described [39].
2.4. Generation of stable cell lines
To generate MAGL-shRNA expressing lentivirus 293 T-packaging
cells (1 × 105 cell/cm2) were transfected with the 5 μg pLKO.1 lentiviral
vector (empty or containing MAGLshRNA), 5 μg psPAX2 vector, 5 μg
pCMV-VSV-G vector and 40 μl polyethylenimine. Twenty-four hours
post-transfection, the medium was replaced with fresh standard
D-MEM and cells were grown for an additional 24 h. The conditioned
medium containing recombinant lentiviruses was collected and filtered
through 0.45 μm-pore-size filters. Samples of these supernatants were
applied immediately to MDA-231-BT, PC3-BT or KHOS cells, which
had been plated 18 h before infection at a density of 1 × 104 cells/cm2.
Polybrene (107,689 Sigma-AldrichDorset, UK)was added to afinal con-
centration of 5 μg/ml, and the lentiviral supernatants were incubated
with the recipient cells. Twenty-four hours after infections, cells were
selected with 1 μg/ml puromycin for 72 h.
2.5. Cancer cell lines and conditioned medium
The osteotropic human MDA-231-BT, human PC3-BT and human
KHOS cells were cultured in standard DMEM and mouse MOS-J cells
were cultured in alpha-MEM (supplemented with 10% FCS, penicillin
and streptomycin). For studies involving conditioned medium, cancer
cells were allowed to grow to 80% confluence and the medium was
refreshed with serum free D-MEM, and then conditioned medium was
removed after 16 h and filtered (0.22 μM filter diameter). Freshly
prepared conditioned medium (20% v/v) was added to osteoclast and
osteoblast cultures and their precursors in standard alpha-MEM supple-
mented. Cultures were then treated with vehicle or test compounds for
the desired period of time.
2.6. Osteoblast cultures
Primary osteoblasts were isolated from the calvarial bones of 2-day-
old mice by sequential collagenase digestion [40]. For bone nodule
assay, osteoblasts (10 × 105 cells/12-well) were cultured in standard
alpha-MEM, supplemented with 10% FCS, penicillin and streptomycin,
β-glycerol phosphate (10 μM) and L-ascorbic acid (50 μg/ml) for up to
21 days with replacement of the culture medium in the presence or ab-
sence of test substances every 48 h. For osteoblast – cancer cell CM sys-
tem, osteoblasts (10 × 104 cells/24-well) were cultured in alpha-MEM,
supplemented with 10% FCS and 1,25-(OH)2-vitamin D3 (10nM) for
up to 5–7 days with replacement of the culturemedium in the presence
or absence of test substances every 48 h. Osteoblast number, differenti-
ation andbonenodule formationwere determined byAlamarBlue, alka-
line phosphatase (Alk Phos) and alizarin red (ALZ) assays, respectively
[40,41].
2.7. Osteoclast cultures
Osteoclast formation, survival and activity were studied using
RANKL and M-CSF generated mouse osteoclasts and bone-marrow cell
– osteoblast co-cultures as previously described in [42]. Briefly, bone
marrow (BM) cells were flushed from the long bones of 3–5 month
old mice and were cultured in standard alpha-MEM supplemented
withmouseM-CSF (100ng/ml). Erythrocyteswere removed and adher-
ent cells were re-suspended in culture medium and counted. For osteo-
clast generation, M-CSF-generated bone marrow macrophages (pre-
osteoclasts) were plated into tissue culture plates (96-well plates, 15
× 103 cells/well; 12-well plates, 150 × 103 cells/well) in standard
alpha-MEM supplemented with M-CSF (25 ng/ml) and RANKL
(100 ng/ml). The macrophage cell line RAW 264.7 was cultured in 96-
well plates (15 × 103 cells/well) in standard alpha-MEM supplemented
with RANKL (100 ng/ml). For studies involving conditioned medium,
conditioned medium from cancer cultures was prepared as described
above then added to osteoclast cultures at a concentration of 10%
(v/v) in standard alpha-MEM. The cultures were terminated by fixation
in 4% paraformaldehyde andwashedwith PBS. TRAcP stainingwas used
to identify multi-nucleated osteoclasts and TRAcP positive cells with 3
or more nuclei were considered to be osteoclasts [43].
2.8. Assessment of cell motility
Cell migration was assessed by wound healing assay. Briefly, cells
were plated into 24-well plates (2–5 × 105 cells/well) and confluent
cell layers were scored with a fine pipette tip to produce a wound. Mi-
gration of cells across the wound was monitored using an Olympus
ScanR time lapse microscope system and percentage of wound closure
were analyzed using the ImageJ program. Cell spreading was assessed
by using the real-time cell analyzer xCELLigence (Roche Applied
Science, UK) [41,44]. Briefly, cells (103 cells/well) were plated into spe-
cialized 16-well plates (Roche Applied Science, UK) in alpha-MEM in
the presence and absence of JZL184 for 2–6 h. Data were analyzed
using the xCELLigence software [44].
2.9. Micro-computed tomography
Ectopic bone formation (tibia and fibula) and trabecular bone pa-
rameters (tibia and femur) were measured using micro-computed to-
mography (microCT) analysis (Skyscan 1076 Brucker, Belgium) set at
50 kV and 200 mA. Skyscan NRecon sofware was used to reconstruct
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and images were analyzed using CTan (Skyscan CTAn, Brucker,
Belgium) [45].
2.10. LC-MS/MS
Liquid chromatography–mass spectrometry (LC-MS/MS) was used
to measure the levels of endocannabinoids as previously described
[23]. Briefly, cell pellets or conditioned medium were re-suspended in
600 μl of Lysis Buffer (10mMTris, 1 mM EDTA, pH= 7.6) and mechan-
ically disrupted using a polytron device (20 Krpm, 30 s, in ice) and by
one-cycle of freeze thawing. Cell lysates were cleared up by centrifuga-
tion (4000 rpm, 5 min, 4 °C) and the supernatants were separated and
stored at−80 °C. Total protein was determined using the BCA kit (Bio
Rad).
2.11. Western blotting
Western blot analysis was used to detect protein expression. Cells
were lysed in a standard buffer (0.1% (w/v) Sodium dodecyl sulfate,
0.5% (w/v) sodium deoxycholate, 1% Triton X-100, 1 μM Ethylenedi-
aminetetraacetic acid, 2% (v/v) protease inhibitor cocktail, 10 μM of so-
dium fluoride and 2% (v/v) phosphatase inhibitor cocktail. Protein
concentrationwas determined using BCA assay (Pierce, USA). Total pro-
tein (60 μg) was resolved by SDS-PAGE (BioRAD, United Kingdom),
immunoblottedwith antibodies, detected using rabbitmonoclonal anti-
bodies (all at 1:1000 dilution, cell Signalling Technology, USA) and
immuno-complexes were visualised by an enhanced chemilumines-
cence (Amersham, UK) on a Syngene GeneGnome imaging system.
The intensity of the bands was quantified using GeneSnap software
(Syngene, UK) and level of actin was used for normalization.
2.12. Measurement of levels of tumour-derived factors
Level of tumour-derived factors in conditioned medium was mea-
sured by using the Proteome Profiler Human XL Cytokine Array Kit
(ARY022, R&D Systems, Abingdon, UK), according to themanufacturer's
instructions.
2.13. Statistical analysis
Data analysis and statistical comparisons between groups were
made by use of Student's t-test or analysis of variance (ANOVA)
followed by Dunnet's post test (SPSS for Windows, version 11). A p-
value value of 0.05 or below was considered statistically significant.
3. Results
3.1. MAGL inhibition reduces migratory and osteolytic features of
osteotropic cancer cells
MAGL is implicated in cancer progression and the administration of
JZL184 in mice reduced tumour growth and overt metastasis in the
human prostate cancer PC3model [1,4]. Metastatic cancer cells of pros-
tate origin including PC3 cells preferably metastasise to bone [8–12],
however the effect of MAGL inhibition on bone metastasis has not
been investigated. Here, we first confirmed that MAGL is expressed in
patients (Supplementary Fig. S1A-D) and mice (Supplementary
Fig. S1E) with prostate cancer, and its expression correlates with the
metastatic potential of osteotropic PC3 cells when compared to poorly
metastatic LNCap cells (Supplementary Fig. S1F). MAGL is expressed
in biopsies from osteosarcoma patients (Supplementary Fig. S2A–B),
and its activity was detected and successfully knocked down in the
human osteotropic sub-clones of prostate PC3 (PC3-BT) and breast
MDA-MB-231 (MDA-231-BT) (Supplementary Fig. S3). In view of
these findings and the fact that cancer cells in the skeleton grow,
move, alter the behaviour of bone cells differently compared to their
parental counterpart [8–10,15,46], we assessed the effect of JZL184 on
the growth and metastatic behaviour of a panel of human and mouse
osteotropic prostate and breast cancer and osteosarcoma cells (Fig. 1,
Fig. S4, and data not shown). JZL184 (1 - 100 μM) reduced the viability
of human, osteotropic prostate PC3-BT and breast MDA-231-BT and the
osteoblast-like osteosarcoma cell line cells Saos2 in a concentration-
dependent manner after continuous exposure for 72 h (Fig. S4A). In
contrast, JZL184 enhanced the viability of the naïve PC3, MDA-231 and
exerted no significant effects on the growth of the highly differentiated
andmetastatic osteosarcoma cells KHOS at concentrations up to 100 μM
(Fig. S4A). Next, we knocked down the protein level of MAGL (Fig. S3A),
and went on to show that both MAGL knockdown and exposure to
JZL184 (3 μM) reduced the directed migration (Fig. 1A), invasion
(Fig. 1B) and growth (Fig. S4) of the osteotropic PC3 and MDA-231
and KHOS. Additionally, exposure of M-CSF pre-treated mouse bone
marrow derived osteoclast precursors to JZL184 (1–3 μM) prior to addi-
tion ofmockorMAGL-deficient prostate PC3-BT, breastMDA-231-BT, or
osteosarcoma KHOS cell lines significantly inhibited osteoclast forma-
tion (Fig. 1C), indicative of an anti-osteolytic effect (Fig. 1D). Together,
these in vitro results suggest that JZL184 may be of benefit in reducing
the ability of tumour cell to cause cancer-associated bone disease in
mouse models of the human breast, prostate and osteosarcoma cell
lines described (Fig. S4).
3.2. JZL184 reduces skeletal tumour growth, metastasis and cachexia and
improves survival
Next, we inoculated mice with the human breast MDA-231-BT and
prostate PC3-BT and osteosarcoma KHOS and the syngeneic osteosar-
comaMOS-J cells, and tested theeffects of JZL184on the initiationandde-
velopment of cancer associated bone disease (Fig. 2A and F). Graphic
representation of intra-cardiac injection of osteotropic human prostate
PC3-BT and breast MDA-231-BT and para-tibial injection of the human
KHOS and mouse MOS-J into mice are shown in Figs. S5, S7 and S8, re-
spectively. The dosing regime of JZL184 have been chosen on the basis
of previous studies that have shown it produced cannabinoid behavioral
effects by increasing the level of the endocannabinoid 2AG [47–50], and
reduced tumour growth and metastasis [4,51,52]. The rationale for
choosing JZL184 at 16 mg/kg, thrice weekly in most of our studies is
that previous studies have reported a near-complete blockade of MAGL
by JZL184 at this dose [47–50]. Administration of JZL184 (16 mg/kg,
thrice weekly) inhibited the skeletal tumour growth (Fig. 2A–C) of the
human prostate PC3-BT, breast MDA-231-BT and osteosarcoma KHOS
cells in immuno-deficient nude mice and mouse MOS-J cells in
immuno-competent mice (Fig. 2A). Representative images from the
osteotropic PC3-BT and osteosarcoma KHOS experiment described are
shown in Fig. 2 panels B and C, respectively. Additionally, treatment
with JZL184(16mg/kg, thriceweekly) reduced the incidenceofboneme-
tastasis of the human osteotropic prostate PC3-BT (Fig. 2D) and breast
MDA-231-BT cells (supplementary Fig. S5A-B), and inhibited the metas-
tasis of the osteosarcoma human KHOS and mouse MOS-J cells to the
lungs (Fig. 2E). JZL184 also reduced cachexia in mice after intra-cardiac
injection of osteotropic MDA-231-BT cells (Fig. S5C), and improved sur-
vival in this model (Fig. S5D) and inmice locally injected with the osteo-
sarcomaKHOS (Fig. 2F). In contrast,mice inoculatedwithMAGLdeficient
KHOS cells exhibited similar tumour growth (supplementary Fig. S6A)
and non-significant reduction in number of lung micro-metastasis (sup-
plementary Fig. S6B) when compared to mock control.
3.3. JZL184 reduces cancer induced bone loss
Detailed microCT analysis of the long bones of mice (Fig. 3A–C)
showed that injection of the human prostate PC3-BT (Fig. 3A), breast
MDA-231-BT (Fig. 3A) and osteosarcoma KHOS (Fig. 3A) cells in
immuno-deficient nude mice caused significant osteolytic bone damage
characterised by significant reduction in bone volume when compared
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Fig. 1. Inhibition of cancer cellmotility and support for osteoclastogenesis byMAGL inhibition. (a–b) Effects of JZL184 (JZL, 10 μM) andMAGL knockdown (KD) on the prostate cancer PC3-
BT, breast cancer MDA-231-BT and osteosarcoma (KHOS) cell migration (a; 12 h) and invasion (b; 48 h) as assessed byWound Healing and Matrigel invasion assays, respectively. (c) In
vitro osteoclastogenesis ofmurineM-CSF- and RANKL-stimulated PC3-BT,MDA-231-BT or KHOS - bonemarrow cell co-cultures treatedwith JZL184 (1-10 μM) for 72h. (d) Representative
images of multi-nucleated osteoclasts as visualised by TRAcP staining (scale bar = 50 μM). Values are expressed as means ± SD and are obtained from 3 different experiments. * p b .01
from control cultures and + p b .01 between two cell types tested.
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to the sham leg and these effects were significantly reduced by adminis-
tration of JZL184 (16mg/kg, thriceweekly). In the osteolytic bonemetas-
tasis models, MDA-231-BT (supplementary Fig. S5E) and PC3-BT
(supplementary Fig. S8D), JZL184 (16 mg/kg, thrice weekly) increased
trabecular number (Tb.N), reduced trabecular separation (Tb.Sp) and in-
creased trabecular connectivity (reduced trabecular pattern factor; Tb.
Pf). Representative microCT images from the MDA-231-BT experiment
described are shown in Fig. 3 (panel D). In the MDA-231-BT model,
JZL184 exerted similar osteoprotective effects in mice at doses of both
8mg/kg and 16mg/kg thriceweekly (supplementary Fig. S5E). Similarly,
JZL184 (16 mg/kg, thrice weekly) increased bone volume (Fig. 3C) and
trabecular connectivity (reduced trabecular pattern factor; Tb.Pf;
Fig. S7C) in the KHOSmouse model. In this model, however, injection of
the human osteosarcoma KHOS cells in these mice enhanced trabecular
thickness and this effect was enhanced by JZL184 treatment (Fig. S7D).
Histological and histomorphometrical analysis of bones revealed that
JZL184 (16 mg/kg, thrice weekly) increased osteoclast (Fig. 3D) and re-
duced osteoblast (Fig. 3E) activity in healthy legs of mice that received
para-tibial injectionof humanKHOSosteosarcomacells buthadno signif-
icant effects on both parameters in legs bearing osteosarcoma KHOS,
prostate PC3-BT or breast MDA-231-BT tumours. In contrast, we ob-
served non-significant increase in bone volume in mice inoculated with
osteolytic MDA-231-BT (supplementary Fig. S6C) or mixed osteoblastic/
osteolytic KHOS cells (data not shown) deficient in MAGL when com-
pared to mock control. Collectively, these results show that JZL184 re-
duces cancer induced bone damage in the mouse models of
osteosarcoma, prostate and breast cancer described.
3.4. JZL184 inhibits cancer-associated ectopic bone formation
In view of the fact that osteosarcoma cells induce the formation of ec-
topic bone in human [53] and in the mouse models used in this study
[54,55], and JZL184 inhibited osteoblast activity in the KHOS osteosar-
coma model (Fig. 3F), we carried out further microCT analysis of
cancer-induced bone formation within the tumour in close proximity to
the fibula and proximal tibia of mice. As shown in Fig. 4, mice that re-
ceived JZL184 (16 mg/kg, thrice weekly) exhibited reduced ectopic
bone volume in both tibia (Fig. 4A) and fibula (Fig. 4C) when compared
to vehicle treated mice. Representative photomicrographs of ectopic
bone formation from the experiment described are shown in Fig. 4,
panels B and D. Next, we carried out additional in vitro studies on the ef-
fects of JZL184 on the ability of calvarialmouse osteoblast and the human
osteoblast-like and early-differentiated osteosarcoma cells Saos2 to form
bone nodule in the presence and absence of derived factors from the
highly metastatic KHOS osteosarcoma cells. These experiments showed
that exposure to JZL184 (1 μM) reduced alkaline phosphatase activity
and bone nodule formation in cultures of mouse osteoblasts (Fig. 4E,
left) and Saos2 (Fig. 4E, right). Similar inhibition in alkaline phosphatase
activity and bone nodule formation was also observed in osteoblasts
(Fig. 4G, left) and Saos2 (Fig. 4G, right) cultured in the presence of condi-
tionedmedium fromKHOSosteosarcoma cells. Interestingly, exposure to
JZL184 (10 μM)hadno significant effects on the viability of calvarial oste-
oblasts in the experimentsdescribedbut amodest reduction in theviabil-
ity of the Saos2 osteosarcoma cells was observed particularly in the
presence of conditioned medium from KHOS osteosarcoma cells
(Fig. 4G, right). Representative photomicrographs of bone nodule forma-
tion from the calvarial osteoblast cultures in the absence or presence of
conditioned medium from KHOS osteosarcoma cells are shown in Fig. 4,
panel F andH, respectively. These results together indicate that exposure
of osteoblasts and early-differentiated osteosarcoma cells to JZL184 re-
duce their ability to differentiate and form bone nodule.
3.5. JZL184 causes paradoxical bone loss by cannabinoid receptor activation
MAGL is responsible for the degradation of 2AG, the
endocannabinoid which activates both Cnr1 and Cnr2 receptors
[19–25]. 2AG is produced within the central nervous system and in
the bone microenvironment by osteoblasts and osteoclasts [19,21–24],
and both cannabinoids receptors Cnr1 and Cnr2 have been implicated
in the regulation of bone cell activity and bone remodelling
[22,28,30,32,33,56–58]. In view of these findings and the present obser-
vation that administration of JZL184 showed a trend towards reduced
cortical (Fig. S7B, left) and trabecular (Fig. S7B, right) bone volume in
non-tumour bearing legs of mice, we carried out additional in vivo ex-
periments to test the effect of JZL184 on bone mass in wild type (wt)
and double Cnr1 and Cnr2 knockout (Cnr1/2−/−) female mice treated.
As shown in Fig. 5, administration of JZL184 (16 mg/kg, thrice weekly)
in wild typemice for 60 days caused bone loss characterised by a signif-
icant reduction in bone volume (Fig. 5A) and trabecular connectivity
(increase in trabecular separation, Fig. 5B) and number (Supplementary
Fig. S9A). In contrast, Cnr1/2−/− female mice treated with JZL184
(16 mg/kg, thrice weekly) were completely protected and exhibited
similar trabecular bone volume and connectivity comparable to vehicle
treated control (Fig. 5A–B). RepresentativemicroCT images from the ex-
periment described are shown in Fig. 5 (panel C). Interestingly, neither
JZL184 treatment nor genetic inactivation of Cnr1 and Cnr2 receptors
resulted in any significant changes in trabecular thickness (Supplemen-
tary Fig. S9B) or cortical bone parameters (data not shown). Histological
and histomorphometrical analysis of bones revealed that JZL184
(16 mg/kg, thrice weekly) increased the activity of both osteoclasts
(Supplementary Fig. S9C) and osteoblasts (Supplementary Fig. S9D),
and these effects were significantly blunted in Cnr1/2−/− mice. To
investigate whether tumour-derived endocannabinoids and/or
host-specific classical cannabinoid receptors Cnr1 and Cnr2 are impli-
cated in the pro-osteolytic action of JZL184, we first used liquid
chromatography–mass spectrometry (LC-MS/MS) to analyze the levels
of endocannabinoids in conditioned medium from the osteolytic MDA-
231-BT cells. This experiment shows that MDA-231-BT cells produce
the endocannabinoid 2AG (Fig. 5D) and its level is significantly in-
creased by addition of the osteolytic factor, RANKL (Fig. 5E). Interest-
ingly, MDA-231-BT-derived 2AG was detected in higher level than
Anandamide (AEA) and the prostaglandin PGE2, but lower level than
Arachidonic acid (AA) (Fig. 5D). Next, we used the mouse calvarial
organ – human cancer cell co-culture model (Fig. 5F) to test if the effect
of MAGL inhibition by JZL184 on cancer-induced osteolysis is mediated
by activation of classical cannabinoid receptors expressed by host cells.
The main advantage of the calvaria organ culture used in this study it
allowed us to examine the effects of JZL184 on osteolytic bone damage
induced by human cancer cells in skeletal tissue derived from both
immuno-competent wild type and Cnr1/2 double knockout mice from
the CD1 background described. These experiments showed that the ad-
dition of the osteolyticMDA-231-BT – but not prostate cancer PC3-BT or
osteosarcoma KHOS (data not shown) - cells to the organ cultures from
wild type female mice caused a decrease in calvarial bone volume (p b
.01) over a 7 day culture period and this effectwas significantly reduced
in organ cultures from Cnr1/2 double knockout female mice (Fig. 5G).
Treatment with JZL184 (1 μM) increased osteolysis even further and
this effect was partially reversed in organ cultures from Cnr1/2−/−
mice cultured with mock or MDA-231 deficient in MAGL (MAGLKD1)
(Fig. 5G), indicative of the involvement of cancer-specific MAGL and
host specific Cnr1 and 2 receptors. Representative microCT images
from the experiment described are shown in Fig. 5H. To examine the
contribution of individual cannabinoid receptors, we pre-treated the
mouse calvarial - MDA-231-BT cancer cell co-cultures with the Cnr1 se-
lective inverse-agonist AM251 or the Cnr2 selective inverse-agonist
AM630 for 1 h prior to the addition of JZL184 for 5 days. As shown in
supplementary Fig. S9, treatment with AM630 (3 μM), and to lesser ex-
tent AM251, significantly blunted the pro-osteolytic action of JZL184 (1
μM). It is important to note that exposure to AM251 and AM630 (3 μM)
significantly reduced the viability ofMDA-231-BT cells under conditions
tested by 27 ± 12% and 37 ± 4% (p b .05), respectively. Interestingly,
pre-treatment of the MDA-231-calvarial bone co-culture with the
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cox1/2 inhibitor Indomethacin (10 μM) failed to protect against JZL184
(3 μM) driven osteolysis (Fig. 5I), excluding the involvement of the
prostaglandin/Cox pathway in the model described.
3.6. JZL184 disrupts cancer cell – osteoclast crosstalk
Analysis of the levels of human cytokines and chemokines in condi-
tionedmedium fromMDA-231-BT revealed that exposure to JZL184 at 1
μM - the concentration that enhanced MDA-231-BT-induced osteolysis
in the calvarial model - increased the levels of MDA-231-BT-derived
vascular endothelial growth factor (VEGF), resistin and to a lesser ex-
tend brain-derived neurotrophic factor (BDNF) and Granulocyte-
macrophage colony-stimulating factor (GM-CSF) (Fig. 5J) - four factors
that are known to enhance osteoclast formation [59–63]. JZL184 (1
μM) also increased the level of sex hormone-binding globulin (SHBG),
a serum glycoprotein that has been associated with bone loss and the
occurrence of fractures. In contrast,we detected a reduction (≤1 fold/ve-
hicle) in the osteoclast inhibitory factors B-cell-activating factor (BAFF)
[64], macrophage Migration Inhibitory Factor (MIF) [65], trefoil factor
family 3 (TFF3) [66], osteopontin (OPN) [67] and myeloperoxidase
(MPO) [68]. Interestingly, JZL184 (1 μM) reduced the level of the pro-
inflammatory TNFα, which is known to both enhance [69] and reduce
[70] osteoclast formation, and induces cell death and apoptosis in cells
of the osteoblast lineage [69,71]. We also carried out quantitative PCR
analysis of MAGL expression in bone marrow cells (BMCs), osteoblasts,
osteoclasts and their precursor cells. As shown in Fig. 6A,mRNA levels of
MAGL in bone marrow cells and calvarial osteoblasts were significantly
higher than in mature osteoclasts and their M-CSF dependent bone
marrow macrophage (osteoclast precursors). Together, these results
suggest that JZL184 disrupts cancer cell – osteoclast crosstalk in
osteolytic environment.
3.7. JZL184 and 2AG exert a biphasic effects on osteoclastogenesis
To investigate the effects of JZL184 on cancer-induced osteoclast for-
mation further, we went on to show that pre-exposure of mouse bone
Fig. 2. JZL184 reduces skeletal tumour growth,metastasis and cachexia and improves survival inmice. (a) Effects of JZL184 (16mg/kg, thriceweekly) on in vivo tumour area (% tissue area)
in the tibial metaphysis of mice after intra-cardiac injection of osteotropic human prostate PC3-BT cells (n=16, 32 days) andMDA-231-BT (n= 16, 55 days) into BALB/c -nu/nu athymic
mice (8weeks old), or intra-tibial injection of thehumanKHOS andmouseMOS-J osteosarcoma intoNMRI athymic nude and C57BL/6jmice, respectively (5weeks old,n=7, 33days). (b-
c) Representative photomicrographs of microCT scan of the trabecular compartment and long bone of the tibial metaphysis of mice after the injection of human osteotropic prostate PC3-
BT cells (b, scale bar = 1 mm) and KHOS osteosarcoma (c, scale bar = 5 mm), respectively. Arrowheads denote tumour body. (d) Development of bone metastasis in mice after the
injection of human osteotropic prostate PC3-BT cells as assessed by changes in photon intensity (photo/s) between day 17 and 24 post cell inoculation. (e) Development of lung
metastasis in mice after the injection of human KHOS osteosarcoma as assessed by the number of macroscopic metastases. (f) Survival of mice treated with JZL184 (16 mg/kg, thrice
weekly) for 33 days after para-tibial injections of the human KHOS cells (n = 7–8) from the experiment described in panels F–H. Values are mean ± SD; * p b .05.
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marrow cells (pre-osteoclasts) to JZL184 (0.1 and 0.3 μM) in the absence
(Fig. 6B, left) or presence of calvarial osteoblasts (Fig. 6B, middle) or a
cocktail of RANKL (50 ng/ml) and M-CSF (25 ng/ml) (Fig. 6B, right) in-
creased the formation of TRAcP positive osteoclasts. At 10 μM, however,
JZL184 significantly reduced osteoclast formation in BMC-osteoblast co-
cultures (Fig. 6B, middle) and in the presence RANKL and M-CSF
(Fig. 5B, right). Although M-CSF dependent bone marrow macrophage
expressed a low level of MAGL mRNA (Fig. 6A), JZL184 (1 - 10 μM)
exerted similar biphasic effects on the ability of these cells to grow
(Fig. 6C, left), spread (Fig. 6C, middle) and form mature osteoclasts in
the presence of RANKL (Fig. 6C, right). We also investigated whether
2AG, the principal endocannabinoid metabolized by MAGL, influence
osteoclastogenesis in the model described. As shown in Fig. 5C, expo-
sure of M-CSF dependent bone marrow macrophage to 2AG (0.1 - 10
μM) enhanced the action of RANKL (100 ng/ml) and M-CSF
(25 ng/ml) on the expression of a panel of osteoclast specific genes
Fig. 3. JZL184 reduces cancer-related osteolytic bone damage inmice. (a-c) Effects of JZL184 (16mg/kg, thrice weekly) on osteolytic bone loss in the tibial metaphysis of mice after intra-
cardiac injection of osteotropic human prostate PC3-BT cells (a, n = 16, 32 days) and MDA-231-BT (b, n = 16, 55 days) into BALB/c -nu/nu athymic mice (c, 8 weeks old), or intra-tibial
injection of thehumanKHOS intoNMRI athymic nude (5weeks old, n=7, 33days). BV/TVwere expressed as changes in values from the tibialmetaphysis of hind limbs of healthymice (a,
PC3-BM and b, MDA-231-BT) or non-tumour-bearing sham control (c, KHOS). (d) RepresentativemicroCT photomicrographs of osteolysis in the tibial metaphysis ofmice frommice after
intra-cardiac injection of osteotropic humanMDA-231-BT (scale bar= 1mm). (e–f) In vivo osteoclast activity (e, Oc.S) and osteoblast activity (f, Ob.S) from tibial metaphysis ofmice from
the experiment described in panels a – d, as assessed by histomorphometrical analysis. Values are mean ± SD; * p b .05. ns denotes not statistically significant.
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(Fig. 6D, left), osteoclast precursor spreading (Fig. 6D, middle) andmat-
uration into osteoclasts (Fig. 6D, right). In the absence of RANKL, 2AG in-
creased macrophage number cultured in M-CSF (100 ng/ml) alone in a
concentration dependent manner (Fig. 6E).
4. Discussion
Previous studies have implicatedMAGL in cancer and itsmetabolites
2AG and free fatty acids in the regulation of bone metabolism [2,5,6].
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However, the role of MAGL in the regulation of skeletal complications
related to primary and secondary cancer in bone remains unknown.
Here, we provide evidence to show that the verified MAGL inhibitor
JZL184 reduces the initiation and progression of bonemetastasis, skele-
tal tumour growth and osteolysis inmousemodels of osteosarcoma and
prostate or breast cancers. Using in vitro studies in cancer and bone cell
cultures, we first show that both stable knockdown and pharmacologi-
cal inhibition of MAGL reduced the ability of osteotropic breast and
prostate cancer cells to migrate, invade and stimulate osteoclastogene-
sis – thus suggesting anti-metastatic and anti-osteolytic effects. This
led us to hypothesise that inhibition of MAGL in cancer and/or bone
cells reduces the metastatic spread and osteolytic features of primary
and secondary cancer in bone in the models described.
Nomura and colleagues have shown that MAGL knockdown and
pharmacological inhibition using JZL184 reduced tumour growth and
metastasis of the PC3 prostate cancer cells in mice [1,4]. Here we
show that MAGL is expressed by osteotropic sub-clones of the prostate
cancer cells PC3 in culture and in the long bone of mice, and systemic
administration of JZL184 suppressed the ability of these cells to
metastasise to the skeleton, growand cause osteolysis inmice. Our pres-
ent data expand on previous observations [1,4] and demonstrate that
JZL184 exerts similar anti-metastatic, anti-tumour and bone preserva-
tion effects in mouse models of the osteoblastic KHOS and osteolytic
MDA-231-BT cells, two established models of primary bone cancer (os-
teosarcoma) and secondary breast cancer metastasis in bone, respec-
tively. In these models, mice received JZL184 also exhibited reduced
cachexia and increased survival. Interestingly, JZL184 treatment signifi-
cantly enhanced trabecular thickness caused by the injection of the
human osteosarcoma KHOS cells. This action of JZL184 was likely due
to combined inhibition of osteosarcoma-induced bone loss and reduc-
tion of tumour growth by this agent rather than direct stimulation of os-
teoblast differentiation and activity. In stark contract, JZL184 inhibited
the formation of cancer associated bone formation within the tumour
body in mice inoculated with KHOS cells, a key feature of osteosarcoma
[53]. Consistently, we show that JZL184 inhibited the ability of primary
osteoblast and early differentiated osteosarcoma cells Saos2 to differen-
tiate and to form bone nodule in the presence and absence of the highly
metastatic osteosarcoma cells KHOS. We excluded the possibility that
toxic effects of JZL184 affects the viability of primary osteoblast,
osteoblast-like and osteosarcoma cells since we have not observed any
changes in cell number in vitro or in vivo.
A surprising result of this study is administration of JZL184 re-
duced bone loss in the osteolytic MDA-231 and osteoblastic KHOS
models without affecting the number or activity of osteoclasts or os-
teoblasts in mice. This led us to speculate that bone preservation in
these mice was mediated by the combined effects of JZL184 on can-
cer and host cells of the tumour microenvironment. The evidence for
this comes from the data that show that inoculation of MAGL defi-
cient cells produced a modest change or no-significant effect on
bone volume in the MDA-231 and KHOS models used (supplemen-
tary Fig. S6). These effects are inconsistent with previous study that
both MAGL knockdown and pharmacological effects reduced tumour
growth in mice [1,4]. We can not readily explain this other than to
speculate that MAGL inhibition in both cancer and host cells may
be needed to exert a significant reduction in many aspects of
cancer-induced bone disease in the highly aggressive mouse models
described. It is also important to note here that the sub-optimal effi-
ciency in the shRNA-mediated knockdown of MAGL expression in the
osteolytic MDA-231-BT (MAGLKD1, 72% reduction) and osteoblastic
KHOS (MAGLKD2, 68% reduction) cells that were used in our studies
may have contributed to the modest effects observed on mice
injected with MAGL deficient cells.
MAGL is responsible for the degradation of the most abundant
endocannabinoid in bone 2AG [19–25], and previous findings have re-
ported increased the local level of 2AG in the skeleton mimicked the
anti-hyperalgesic effect of 2AG via a Cnr2 receptor-dependent mecha-
nism [72]. Equipped with the knowledge that MAGL metabolites such
as 2AG, AEA and others acts at both classical Cnr1 and 2 receptors
bone loss [20–25,28] - albeit with different degree of selectivity
[73,74], and inactivation of Cnr1, Cnr2 or both receptors has been
found to influence peak bone mass and age-related bone loss
[19–25,28–33], we hypothesised that MAGL inhibition induces bone
loss via an effect that dependent at least in part on the skeletal cannabi-
noid receptors. In support of this hypothesis, we have shown that bone
marrow cells, osteoblasts and osteoclasts express MAGL and exposure
to JZL184 at nanomolar concentrations induces the expression of osteo-
clast specific genes, enhances RANKL- and osteoblast-induced osteo-
clast formation and causes bone loss in the presence and absence of
osteolytic cancer cells. Most importantly, the latter effect was signifi-
cantly blunted in mice or calvarial bone organ cultures deficient in
both Cnr1 and Cnr2 cannabinoid receptors. Interestingly, we have also
observed that pre-exposure of calvarial bone and osteolytic cancer
cells to the Cnr2 selective inverse agonist AM630 was more effective
in blunting the pro-osteolytic action of JZL184 when compared to treat-
ment with the Cnr1 selective AM251. It is tempting to speculate about
the involvement of an individual cannabinoid receptor in the pro-
osteolytic action of JZL187 in our experiments since these agents have
been previously shown to act on multiple targets at concentrations
tested. The fact that JZL184 failed to completely reverse osteolysis in
calvarial bone from Cnr1/2 knockout mice when compared to wild
type control have led us to examine the level of tumour-derived pro-
inflammatory mediators that we and others have reported to regulate
the interaction between osteotropic cancer cells and osteoclasts
[8–10,15,46,75]. These experiments revealed that JZL184 regulates the
production of tumour-derived osteolytic and pro-osteoblastic factors.
The marked increase in the levels of osteolytic factors such as VEGF
and resistin and may account for JZL184 pro-osteoclast action and/or
its failure to inhibit osteoclastogenesis in the presence of cancer cells
in mice. VEGF, resistin and other detected factors including osteopontin
are known to enhance the proliferation, maturation and RANKL by oste-
oblasts [59,76], a possiblemechanism forMDA-231-BT and JZL184 asso-
ciated bone loss in the model described. Another plausible mechanism
may involve the reduction of host- and/or tumour-derived free fatty
acids, key metabolites of MAGL that have been shown to regulate
bone growth and remodelling [77–79]. Receptors and fatty acid sensors
are expressed by osteoclasts, osteoblasts and their precursors [80,81],
and a number of in vitro studies have shown that FFA reduce or stimu-
late osteoclastogenesis depending on cell type and culture conditions
[80,81]. Another intriguing finding is both JZL184 and 2AG stimulated
the growth of M-CSF dependent bone marrow macrophage at micro-
molar concentrations that inhibited osteoclast formation. Bearing in
mind that a number of studies have previously reported that 2AG
Fig. 4. JZL184 reduces osteosarcoma-induced ectopic bone formation in mice. (a–d) Effects of JZL184 (16mg/kg, thrice weekly) on ectopic bone volume (BV) in the tumour-bearing tibia
(a) and fibula (b) from mice after para-tibial injections of human KHOS osteosarcoma cells (n = 7, 33 days) from the experiment described in Fig. 3, panel c. Representative
photomicrographs of microCT scan of ectopic bone in tibia (b) and fibula (d) from the experiment described are shown on the left and right panels (scale bar = 1 mm), respectively.
(e) In vitro differentiation, bone nodule formation and viability of calvarial osteoblasts (left) and the human osteoblast-like Saos-2 osteosarcoma cells (right) treated with JZL184 (0.1
μM) 12 (Saos2) or 21 (osteoblasts) days. (f) Representative images of bone nodules in osteoblast cultures that described in panel e as visualised by Alazarin Red staining (scale bar =
5 mm). (g) In vitro differentiation, bone nodule formation and viability of calvarial osteoblasts (left) and the human osteoblast-like Saos-2 osteosarcoma cells (right) treated with
JZL184 (0.1 μM) 12 (Saos2) or 21 (osteoblasts) days in the presence of conditioned medium from the human KHOS cells. (h) Representative images of bone nodules in osteoblast
cultures that described in panel g as visualised by Alazarin Red staining (scale bar = 5 mm). Cell differentiation, bone nodule formation and viability were assessed by alkaline
phosphatase, Alazarin Red and AlamarBlue assays, respectively (n= 3). Data are mean ± SD, * p b .05, **, p b .01.
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enhances macrophage function [82–85], it is tempting to speculate that
macrophage-derived 2AG - alone or in cooperation with a cocktail of
pro-inflammatorymediators - inhibit osteoclast differentiation tomain-
tain macrophage function in our models [86]. A plethora of other mem-
bers of the serine hydrolase family of enzymes, intracellular signalling
pathways including NFκB and β-catenin and physiological mediators
such as nitric oxide and eicosanoids have been implicated in the action
of JZL184 [52,87–89]. Since all of these mediators have an inflammatory
and immune component, it is possible theymay play a role in the effects
of JZL184 on initiation and progression of cancer associated bone dis-
ease in themodels described. Thus, furthermechanistic studies arewar-
ranted and on-going.
Fig. 5. JZL184 induces bone loss in vivo and ex vivo by cannabinoid receptor activation. (a–c) Bone volume (a, BV/TV) and trabecular separation (b, Tb.Sp) in the tibia of wild type (wt) and
Cnr1 and 2 double knockout (Cnr1/2−/−) mice treated with JZL184 (16mg/kg, thrice weekly, n=8) for 60 days. Representative photomicrographs of microCT scan of trabecular bone in
the tibiametaphysis of mice from the experiment described are shown in panel c (scale bar= 1mm). (d) Levels of tumour-derived 2AG, AA, AEA and PGE2 in conditioned medium from
osteotropic humanMDA-231-BT cells as assessed by LC-MS/MS. (e) Levels of tumour-derived 2AG inMDA-231-BT cells and conditionedmedium cultured in the presence and absence of
RANKL (25 ng/ml) for 48 h, as assessed by LC-MS/MS. (f) Graphic representation of mouse calvaria organ – cancer cell co-culture system. (g - h) Percentage change in bone volume in
mouse calvaria bone from wild type (wt) and Cnr1 and 2 double knockout (Cnr1/2−/−) co-cultured with mock or MAGL deficient (KD) MDA-231-BT cells in the presence and absence
of vehicle or JZL184 (1 μM). Representative photomicrographs of microCT scan of mouse calvaria bone from the experiment described in panel h (scale bar = 1 mm). (i) Percentage
change in bone volume in mouse calvaria bone from wild type mice co-cultured with mock MDA-231-BT cells in the presence and absence of vehicle or the Cox inhibitor
Indomethacin (10 μM). (j) Levels of tumour-derived factors assessed by Proteome Profiler Human XL Cytokine Array Kit. Dotted line denotes expression in vehicle treated cells. Refer
to text for abbreviations. Data are mean ± SD, *p b .05 and **p b .01 from control; +p b .05 from wild type (wt); $p b .00 from vehicle treated Cnr1/2−/−.
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Collectively, the results presented in this study extend our and
others previous findings on the role endocannabinoids and their recep-
tors in the skeleton [17–19], and show that the verified MAGL inhibitor
JZL184 exerts anti-tumour and anti-metastatic effects, alleviates
cachexia and prolongs survival in the cancer models described, but it
causes bone loss in healthy mice. When combined with previous
study [1,4], thesefindings reveal a complex function ofMAGL in the reg-
ulation of normal and cancer-related bone remodelling (Fig. 7), offer a
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new insight into the role of the skeletal endocannabinoid system in the
crosstalk between cancer and bone cells and implies that MAGL inhibi-
tors such as JZL184, or its novel analogues, may be of value in the treat-
ment of skeletal complications associatedwith primary bone cancer and
bonemetastasis, but caution against the potential detrimental effects of
therapeutic targeting of MAGL for the treatment of bone disorders. For
that, further mechanistic studies are needed.
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Fig. 6. JZL184 and 2AGexert a biphasic effects on osteoclastogenesis in vitro. (a) Expression ofmRNAofMAGL in cultures ofmurine bonemarrow cells (BMC), calvarial osteoblasts (OB),M-
CSF-stimulated bonemarrowmacrophage (mac, osteoclast precursors),M-CSF- andRANKL-stimulated bonemarrowmacrophage (maturemultinucleated osteoclast, OC) and brain tissue
as assessed byqPCR. Data aremean±SD, *pb .01 frombrain;+pb .01 fromMac andOC; #p b .01 fromOB. (b) In vitro osteoclast formation in bonemarrow cells treatedwith JZL184 (0–10
μM) cultured in the absence (left) or present of calvarial osteoblasts (middle) orM-CSF and RANKL (100 ng/ml) (right) for 7 days. **p b .05 from vehicle (osteoblast culture);+p b .01 from
vehicle (RANKL stimulated BMC). (c) In vitro pre-osteoclast spreading (left) and macrophage growth (middle) and osteoclast formation (right) in cultures of murine M-CSF-dependent
bone marrow macrophage (pre-osteoclasts) after exposure to JZL184 (0–10 μM) in the presence or absence of RANKL (100 ng/ml) for 6, 48 or 72 h, respectively. Pre-osteoclast
spreading and growth and osteoclast formation were assessed by real-time cell analyzer xCELLigence, AlamarBlue assay and TRAcP staining, respectively. *p b .05 from vehicle; +p b
.01 from vehicle (RANKL and/or M-CSF stimulated BMC). (d) Expression of mRNA of osteoclast specific genes in cultures of murine M-CSF- and RANKL-stimulated bone marrow
treated with vehicle or 2AG (0.1 μM) after 24 h as assessed by qPCR. *p b .05 from vehicle. (e) In vitro pre-osteoclast spreading (middle) osteoclast formation (right) in cultures of
murine M-CSF- and RANKL-stimulated bone marrow treated with vehicle or 2AG at the indicated concentrations assessed as described above. *p b .05 from vehicle; $p b .01 from
JZL184 treated cultures. (f) In vitro growth of murine M-CSF-dependent bone marrow macrophage treated with vehicle or 2AG at the indicated concentrations as assessed by
AlamarBlue assay. *p b .05 from vehicle.
Fig. 7. A Schematicmodel of the effects of MAGL inhibition on the interactions between cancer – bone cells in the bonemetastaticmicroenvironment. MAGL inhibition by JZL184 reduced
prostate and prostate osteolytic bone damage and formation of osteosarcoma associated bone formation by predominately inhibiting skeletal tumour growth and metastasis. In the
absence of cancer, JZL184 increases osteoclastogenesis and exerts a paradoxical reduction of bone volume via an effect that is mediated by classical skeletal receptors. The proposed
model - when combined with previous studies in models of prostate cancer [1,4] and bone remodelling [20–23] – suggests that targeting MAGL may be of value in the treatment of
cancer associated bone disease; however, activation of the skeletal endocannabinoid system may limit the usefulness of MAGL inhibitors as osteoprotective agents. $ denotes studies in
models of prostate cancer [1,4] and * denotes studies in models of bone remodelling [20–23].
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Appendix A. Supplementary data
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.ebiom.2019.05.048.
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